Genetic Susceptibility to Factor VIII Inhibitors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00344435|
Recruitment Status : Completed
First Posted : June 26, 2006
Last Update Posted : April 5, 2018
This international study will identify genetic factors that may influence the development of inhibitory antibodies in patients with hemophilia A after treatment with factor VIII. Bleeding episodes in patients with inhibitors are often more difficult to treat. Previous research indicates that genetic factors play a role in the development of inhibitors. A better understanding of the influence of genes in this treatment complication may be helpful in predicting, treating or preventing inhibitors.
People in families in which one or more members have severe factor VIII deficiency and one or more have a history of an inhibitor may be eligible for this study. Participants fill out a form with questions about the person's relationship to other family members taking part in the study. Those with hemophilia provide a brief medical history, including hemophilia-related information, inhibitor history and the presence of other conditions such as hepatitis C and HIV. All participants have a blood sample taken for laboratory and research tests.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||1187 participants|
|Official Title:||Factor VIII Inhibitor Formation: Identifying Predisposing Genetic Factors|
|Study Start Date :||May 24, 2005|
|Study Completion Date :||April 5, 2016|
U.S. FDA Resources
- Collection from 3500 donors [ Time Frame: Every six months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00344435
|University Hospital, University of Lund|
|Principal Investigator:||Janelle Cortner, Ph.D.||National Cancer Institute (NCI)|